Context Therapeutics, Inc. CNTX 深 沪
等待开盘 03-26 09:30:00 美东时间
2.67
-0.510
-16.04%
华盛通- 最 高3.33
- 今 开3.22
- 成交量 171.98万股
- 最 低 2.5801
- 昨 收 3.18
- 总市值 2.45亿
- 52周最高 3.62
- 市盈率 静 --
- 换手率 1.87%
- 52周最低 0.49
- 委 比 79.45%
- 总股本 9187.92万
- 历史最高 10.87
- 量 比 2.94
- 振 幅 23.58%
- 历史最低 0.47
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7
Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight and raises the price target from $4 to $7.
03-24 20:59
Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 34.62 percent.
03-24 04:20
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7
Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.
2025-12-22 20:25
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.
2025-11-06 19:52
Context Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 9.89 percent. This is a 54.55 percent increase over losses of $(0.22) per share
2025-11-06 06:02
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Inc. announced its participation in two upcoming investor conferences: the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, November 10-12, 2025, featuring a Fireside Chat on November 10 at 3:00 PM ET and 1x1 meetings, and the Stifel 2025 Healthcare Conference in New York, November 11-13, 2025, with a presentation on November 12 at 10:00 AM ET and 1x1 meetings. A live webcast will be available on the Company’...
2025-10-28 11:30
Context Therapeutics Regains Nasdaq Compliance
The latest update is out from Context Therapeutics ( ($CNTX) ). Context Therape...
2025-10-21 06:25
